- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02448641
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke (ACTIsSIMA)
A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind, sham-surgery controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke. The study will be conducted at approximately 65 sites in the United States.
Two cohorts, Group 1 (2.5 and 5 million SB623 cells combined) and Group 2 (sham placebo), will be included in this study. Subjects who are randomized into this study will receive either 2.5 million SB623 cells, 5 million SB623 cells or sham surgery at a 1:1:1 randomization ratio. Randomization will be performed via an interactive web/voice response system (IXRS), stratified by Screening mRS score (recorded in the IXRS at the clinical site).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
- University of Alabama at Birmingham
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham (Surgical/Assessment)
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Xenoscience, Inc. (Assessment)
-
-
California
-
Carlsbad, California, United States, 92011
- The Research Center of Southern California (Assessment)
-
Downey, California, United States, 90242
- Rancho Los Amigos National Rehab Center
-
Fresno, California, United States, 93710
- Neuro-Pain Medical Center (Assessment)
-
Fresno, California, United States, 95710
- Neuro Pain Medical Center
-
Irvine, California, United States
- University of California Irvine
-
Los Angeles, California, United States
- UCLA Medical Center
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center (Assessment/Surgical)
-
Orange, California, United States, 92868
- University of California Irvine (Assessment)
-
Placentia, California, United States, 92870
- Westview Clinical Research (Assessment)
-
Santa Monica, California, United States, 90404
- Providence Saint John's Health Center (Assessment)
-
Santa Monica, California, United States, 90404
- Providence St. John's Health Center (Surgical)
-
Santa Monica, California, United States
- Providence St. Johns Health Center
-
Stanford, California, United States, 94305
- Stanford Health Care (Surgical/Assessment)
-
-
Connecticut
-
Stamford, Connecticut, United States, 06905
- New England Institute for Clinical Research (Assessment)
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar National Rehabilitation Hospital (Assessment)
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine (Assessment/Surgical)
-
Miami, Florida, United States
- University of Miami Jackson Memorial Hospital
-
Panama City, Florida, United States, 32405
- NeuroMedical Research Institute (Assessment)
-
Port Charlotte, Florida, United States, 33952
- Medsol Clinical Research Center (Assessment)
-
Port Charlotte, Florida, United States, 33952
- Neurostudies, Inc. (Assessment)
-
Tampa, Florida, United States, 33606
- University of South Florida (Assessment)
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital (Assessment)
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital (Surgical)
-
Gainesville, Georgia, United States, 30501
- Center for Advanced Research and Education (Assessment)
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital (Surgical)
-
Chicago, Illinois, United States, 60637
- University of Chicago Medical Center (Assessment)
-
Chicago, Illinois, United States, 60637
- University of Chicago Medical Center (Surgical)
-
Chicago, Illinois, United States
- Rehabilitation Institute of Chicago
-
Northbrook, Illinois, United States, 60062
- Consultants in Neurology, Ltd. (Assessment)
-
Peoria, Illinois, United States, 61637
- OSF Saint Francis Healthcare System (Assessment)
-
-
Indiana
-
Elkhart, Indiana, United States, 46514
- Indiana Medical Research, Elkhart Clinic (Assessment)
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center (Surgical)
-
Overland Park, Kansas, United States, 66211
- Kansas Institute of Research (Assessment)
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky Hospital (Surgical)
-
Louisville, Kentucky, United States, 40202
- University of Louisville Clinical Trials Unit (Assessment)
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71301
- NeuroMedical Clinic of Central Louisiana (Assessment)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center (Surgical)
-
-
Michigan
-
Detroit, Michigan, United States
- Henry Ford Hospital
-
Detroit, Michigan, United States, 48201
- Wayne State University (Assessment)
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System (Assessment)
-
-
New Jersey
-
Newark, New Jersey, United States, 07013
- Rutgers New Jersey Medical School (Assessment)
-
-
New York
-
New York, New York, United States, 10016
- New York University Langone Medical Center (Surgical/Assessment)
-
New York, New York, United States
- NYU Langone Medical Center
-
White Plains, New York, United States, 10605
- The Burke Rehabilitation Hospital (Assessment)
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Carolinas Rehabilitation (Assessment)
-
-
Ohio
-
Akron, Ohio, United States, 44320
- Neurology and Neuroscience Associates
-
Akron, Ohio, United States, 44320
- Neurology and Neuroscience Associates, Inc. (Assessment)
-
Cleveland, Ohio, United States, 44106
- University Hospital Case Medical Center (Surgical)
-
Toledo, Ohio, United States, 43614
- University of Toledo Medical Center (Assessment)
-
-
Pennsylvania
-
Elkins Park, Pennsylvania, United States, 19006
- Moss Rehab (Assessment)
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania (Assessment)
-
Philadelphia, Pennsylvania, United States, 19106
- Pennsylvania Hospital (Surgical)
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Comprehensive Stroke Center (Assessment)
-
Philadelphia, Pennsylvania, United States
- Pennsylvania Hospital
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center (Surgical/Assessment))
-
Willow Grove, Pennsylvania, United States, 19090
- Abington Neurological Associates (Assessment)
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina (Surgical)
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
- Chattanooga Center for Neurologic Research (Assessment)
-
-
Texas
-
Dallas, Texas, United States
- University of Texas Medical School
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center at Houston (Assessment/Surgical)
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University
-
Morgantown, West Virginia, United States, 26506
- West Virginia University Hospitals (Assessment)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years, inclusive
- Documented history of completed ischemic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement, with correlated findings by MRI
- Between 6 and 90 months (7.5 years) post-stroke, and having a chronic motor neurological deficit
- Neurological motor deficit substantially due to incident stroke
- Modified Rankin Score of 2-4
- Require Motricity Index 30-75 (UE Scale) or 27-74 (LE Scale)
- Able to undergo all planned neurological assessments
- Able and willing to undergo magneti resonance imaging (MRI) with contrast and computed tomography (CT)
- Agree that use of antiplatelet, anti-coagulant, or non-steroidal anti-inflammatory drugs to be determined by the local medical staff and in accordance with the ACCP 2012 guideline "Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", if applicable , provided that no antiplatelet, anti-coagulant, or non-steroidal anti-inflammatory drugs are to be restarted post-surgery until after the Day 8 MRI is read and are determined to be safe to re-start
- Subjects must have had physical therapy prior to entry (and be willing to continue to the extent possible)
- Must be willing to discontinue herbal or non-traditional medicines for 1 week before and 1 week after the surgical procedure and be willing to continue to the extent possible
- Ability of patient or legal authorized representative to understand and sign an Informed Consent
Exclusion Criteria:
- History or presence of any other major neurological disease other than stroke
- Cerebral infarct size >150 cm3 measured by MRI
- Primary intracerebral hemorrhage
- Myocardial infarction within prior 6 mos.
- Malignancy unless in remission >5 yrs.
- Clinically significant finding on MRI of brain not related to stroke
- Any seizures in the 3 months prior to Screening
- More than 5 degrees of contracture at shoulder, elbow, wrist, fingers, hip, knee and ankle
- Other neurologic, neuromuscular or orthopedic disease that limits motor function
- Uncontrolled systemic illness, including, but not limited to: hypertension; diabetes; renal, hepatic, or cardiac failure
- Positive findings on tests for occult malignancy, unless a non-malignant etiology is confirmed
- Uncontrolled major psychiatric illness, including depression symptoms (CESD R Scale of ≥16 is exclusionary)
- Total bilirubin >1.9 mg/dL at Screening
- Serum creatinine >1.5 mg/dL at Screening
- Hemoglobin <10.0 g/dL at Screening
- Absolute neutrophil count <2000 /mm3 at Screening
- Absolute lymphocytes <800 /mm3 at Screening
- Platelet count <100,000 /mm3 at Screening
- Liver disease supported by AST (SGOT) or ALT (SGPT) ≥2.5 x upper limit of normal at Screening
- Serum calcium >11.5 mg/dL at Screening
- International Normalized Ratio of Prothrombin Time (INR) >1.2 at Screening if the patient does not take anticoagulants; for patients on anticoagulants, INR must be confirmed to be ≤1.2 prior to surgery
- Presence of craniectomy or other contraindication to stereotactic surgery
- Participation in any other investigational trial within 4 weeks of initial screening and within 7 weeks of Baseline visit
- Botulinum toxin injection, phenol injection, intrathecal baclofen, or any other interventional treatments for spasticity (except bracing and splinting) 16 weeks prior to the Baseline visit
- Substance use disorder (per DSM-V criteria, including drug or alcohol)
- Contraindications to head MRI (with constrast) or CT
- Pregnant or lactating
- Female patients of childbearing potential unwilling to use an adequate birth control method during the 12 months of the study
- Any other condition or situation that the investigator believes may interfere with the safety of the subject or the intent and conduct of the study
- Any prior SB623 cell implantation and/or any prior stem cell treatment for stroke or other reason regardless of mode of administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SB623 Implant (2.5M)
2.5 million SB623 cells
|
2.5 million SB623 cells
|
Experimental: SB623 Implant (5.0M)
5 million SB623 cells
|
5 million SB623 cells
|
Sham Comparator: Sham Control
Sham surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline
Time Frame: 6 months
|
The FMMS is used as a clinical measure of body function impairment after stroke that assesses several dimensions of motor impairment, including range of motion in both upper and lower limbs, reflex activity, volitional movement, and co-ordination. The FMMS motor component consists of the 33-item upper extremity subscale (UE-FMMS) and the 17-item lower extremity subscale (LE-FMMS). Items were scored on a 3-point ordinal scale: 0= cannot perform; 1= partial motion; 2= full motion Individual items were then summed to determine scores for the 2 subscale scores, as well as a motor total score (total of all item scores including the 2 subscales UE-FMMS and LE-FMMS). As a result, the UE-FMMS subscale score ranged from 0 to 66 and the LE-FMMS subscale score ranged from 0 to 34. The FMMS motor total score ranged from 0 (hemiplegia) to a maximum of 100 points (normal motor performance). Responders: subjects whose FMMS motor total score improve by ≥10 points at Month 6 from Baseline |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Scale Response: The Proportion of Subjects That Improved at Least One Point on the mRS From Baseline
Time Frame: 6 months
|
Responders: The subjects that improved at least one point on the mRS from Baseline Modified Rankin Scale (mRS): This scale is used to measure the degree of disability or dependence in the daily activities of people who had suffered a stroke. The mRS is an ordinal scale from 0 (no symptoms at all) to 5 (severe disability; requiring constant nursing care and attention, bedridden, incontinent) with a sixth category of death. |
6 months
|
The Proportion of Subjects That Improved at Least 6 Points From Baseline on the ARAT Total Score at the Affected Side
Time Frame: 6 months
|
Responders: The subjects that improved at least 6 points from Baseline on the ARAT total score at the affected side. Action Research Arm Test (ARAT): The test was scored for left and right side separately. Performance on each item was rated on a 4-point ordinal scale ranging from: 3 (performed test normally in less than 5 seconds); 2 (completed test, but took abnormally long or had great difficult, with time varying from 5 to 60 seconds; 1 (performed test partially); 0 (could perform no part of the test). The ARAT is a 19-item measure divided into 4 subtests: Grasp subscale (with 6 items and a score range of 0 to 18); Grip subscale with 4 items and a score range of 0 to 12); Pinch subscale with 6 items and a score range of 0 to 18); Gross arm movement subscale (with 3 items and a score range of 0 to 9). The maximum score on the ARAT is 57 points (possible range 0 to 57) for each side. |
6 months
|
The Proportion of Subjects That Improved at Least 1 Functional Level From Baseline on Gait Velocity
Time Frame: 6 months
|
Responders: The subjects that improved at least 1 functional level (eg, from < 0.4 m/s to 0.4-0.8 m/s or from 0.4-0.8 m/s to > 0.8 m/s) from Baseline on Gait Velocity. Gait Velocity was measured on a standard 10 meter walk. Two trials were tested and the average result from both was used for analysis |
6 months
|
Neurological Quality of Life Response: T-scores of the Change From Baseline in the 2 Sub-domains (Upper Extremity Function and Lower Extremity Function)
Time Frame: 6 Months
|
The Neurological Quality of Life (NeuroQOL) was used as a measure of change in the levels of Quality of Life, Satisfaction and Participation, secondary to improvements in the subject's upper and lower extremity motor function.
NeuroQOL is summation of item scores for upper extremity (8 terms: score 8 - 40) and lower extremity (8 items: score 8 - 40) separately.
The item scores are on a 1 to 5 scale (1 = unable to do; 2 = with much difficulty; 3 = with some difficulty; 4 = with little difficulty; 5 = without any difficulty).
The result provided here shows NeuroQOL score converted to T-score.
The range for Upper extremity T-score and Lower extremity T-score are 12.8 to 53.8 and 16.5 to 58.6 respectively.
|
6 Months
|
Global Rating of Perceived Change (GRPC): The Proportion of Subjects Scoring Either 7 or 6 on the Global Rating of Perceived Change by Both Subject and Clinician
Time Frame: 6 Months (LOCF)
|
Responders: Participants who scored either 7 [much better] or 6 [a little better, meaningful]) Global Rating of Perceived Change from Baseline: Subjects and Clinicians were asked about perceived changes in their motor function by comparing "how well they are doing compared to before the surgical procedure". The Subject Global Rating of Perceived Change was completed by the subject (or by the caregiver using the subject's answers). The following 7-point Likert scale was used: Score 7 (much better); Score 6 (a little better, meaningful); Score 5 (a little better, not meaningful); Score 4 (about the same); Score 3 (a little worse, not meaningful); Score 2 (a little worse, meaningful); Score 1 (much worse) |
6 Months (LOCF)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional Analysis (MMRM), Fugl-Meyer Motor Scale (FMMS)
Time Frame: 6 Months
|
An additional analysis using mixed model for repeated measures (MMRM) was performed treating the change from Baseline in FMMS total score as a continuous outcome (dependent) variable.
The independent variables were treatment, visit, treatment-by-visit interaction, and pooled surgical site as effects, and Baseline FMMS total score and Baseline mRS score as covariates.
Least-squares means (LS-mean) with SE was calculated for the change from baseline measurements.
|
6 Months
|
Proportion of Subjects Whose FMMS Motor Total Score Improve by ≥10 Points at Month 6 From Baseline (Per Protocol Population)
Time Frame: Month 6
|
Responders: subjects whose FMMS motor total score improve by ≥10 points at Month 6 from Baseline
|
Month 6
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gary Steinberg, MD, PhD, Stanford Hospital and Clinics, School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SB-STR02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Ischemic Stroke
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of WashingtonRecruitingStroke, Ischemic | Chronic StrokeUnited States
-
Suzhou Neuralstem BiopharmaceuticalsUnknownIschemic Motor Stroke, ChronicChina
-
Icahn School of Medicine at Mount SinaiRecruitingChronic Ischemic StrokeUnited States
-
MedStar National Rehabilitation NetworkEnrolling by invitationStroke, Ischemic | Chronic Stroke | Ambulation Disorder, NeurologicUnited States
-
Hopstem Biotechnology Inc.Recruiting
-
SanBio, Inc.Completed
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
Clinical Trials on SB623 Implant (2.5M)
-
SanBio, Inc.Completed
-
SanBio, Inc.CompletedTraumatic Brain InjuryUnited States, Japan, Ukraine
-
Aula Dental AvanzadaRecruiting
-
University of Sao PauloCompletedCataract | AstigmatismBrazil
-
Aula Dental AvanzadaCompleted
-
Mentor Worldwide, LLCWithdrawnAugmentation | Augmentation Revision | General Breast Enlargement | Post-lactational Involution | AsymmetryUnited States
-
ZimVieCompletedPartial Edentulism | Tooth DiseaseUnited States
-
Ideal Implant IncorporatedCompletedBreast ImplantsUnited States
-
University of BernNot yet recruitingComplications | Patient Reported Outcome Measures | Cost-Benefit Analysis | Cost-effectiveness | Esthetic Zone | Single Tooth Dental Implant | Single Tooth Lost | Accuracy of Dental Implants | Dimensional Changes | Implant Survival and Success | Frequency of Treatment ProtocolSwitzerland
-
Cairo UniversityNot yet recruitingEdentulous; Alveolar Process, Atrophy